Core Insights - Adlai Nortye Ltd. has appointed Dr. Archie Tse as Head of Research & Development, effective March 29, 2024, to enhance its innovative cancer therapy development efforts [1][3]. Company Overview - Adlai Nortye is a clinical-stage biotechnology company focused on developing innovative cancer therapies, with R&D centers in New Jersey, US, and Hangzhou, China [4]. - The company has a robust pipeline consisting of six drug candidates aimed at various tumor types [4]. Leadership and Expertise - Dr. Archie Tse holds both M.D. and Ph.D. degrees and has extensive experience in oncology drug development, having previously served in leadership roles at CStone Pharmaceuticals, Merck, and Daiichi Sankyo [2]. - His expertise includes managing the advancement of oncology drugs across all development stages, including small molecule therapies and cancer vaccines [2]. Strategic Goals - The company aims to transform deadly cancer into a chronic and eventually curable disease through innovative therapies [5]. - Adlai Nortye is actively seeking partnerships with leading pharmaceutical companies like Eisai and Novartis to maximize the potential of its pipeline programs [5].